Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebivolol vs Telmisartan on Central Blood Pressure in Hypertension
NCT05328310Active, not recruiting
- Sponsor
- Korea University Anam Hospital
- Start
- Jan 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nebivolol in hypertension (HTN), sponsored by Korea University Anam Hospital. Primary endpoint: Central Blood Pressure at 12 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
nebivolol
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05328310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05328310.